About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« USPTO News Briefs | Main | Guest Post -- The Emergent Microbiome: A Revolution for the Life Sciences – Part II, 2015 Patent Trends »

August 10, 2015

Comments

My major concern on these ennovation is that as we know that micro-organism can mutate/have the ability to mutate. Now that we are trying to develop therapeutic drugs are we not giving them the amunition to mutate as well for most of the drugs are oral and the hurb of most micro-ogarnism are in the stomach.Would that not cause major complications on the normal flora of the organs that we rely on for our digestion and absorption of nutrients or am i far fetched in that for there will be clinical trial to monitor all of that?

Very interesting post, thanks. Also, maybe I missed it in the article, but I'm wondering why it focuses on Connecticut??

The comments to this entry are closed.

April 2025

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30